中国的药物监管者接受新的静脉瘤治疗高肺癌的申请。 China's drug regulator accepts new application for ivonescimab to treat advanced lung cancer.

中国国家医疗产品管理局已接受新的静脉瘤药物申请,这是一种治疗高端典型非小细胞肺癌的治疗方法。 The National Medical Products Administration in China has accepted a new drug application for ivonescimab, a treatment for advanced squamous non-small cell lung cancer. 这是继先前核准其他肺癌治疗后接受的第三份IVONESCIMAB申请。 This is the third application accepted for ivonescimab, following previous approvals for other lung cancer treatments. 该申请基于成功的III期试验,该试验显示,与化疗结合的IVONESCIMAB的效果优于其他PD-1治疗方法. The application is based on a successful Phase III trial showing ivonescimab combined with chemotherapy outperformed another PD-1 treatment. 该药物正在全球12次临床试验中进行测试。 The drug is being tested in over 12 clinical trials globally.